drugset / Trial / NCT00362466
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients. The safety of this treatment will also be studied.
Timeline
- Start
- 2007-04
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Imatinib | Small molecule | 200 mg | Oral |
| Comparator | Imatinib | Small molecule | 800 mg | Oral |
| Comparator | dasatinib anhydrous | Small molecule | 50 mg | Oral |
| Comparator | dasatinib anhydrous | Small molecule | 180 mg | Oral |